EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

Most patients with hypertension require more than one agent to control blood pressure (BP). The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor blocker olmesartan medoxomil in combination with hydrochlorothiazide (HCTZ). This was a randomized, double-blind, factorial design study. After a placebo run-in period, eligible patients (n=502) with a baseline mean seated diastolic blood pressure (SeDBP) of 100 to 115 mm Hg were randomized to one of 12 groups: placebo, olmesartan medoxomil monotherapy (10, 20, or 40 mg/day), HCTZ monotherapy (12,5 or 25 mg/day), or one of six groups of olmesar-tan medoxomil/HCTZ combination therapy. The primary endpoint was the change in mean trough SeDBP from baseline at week 8. Statistical analyses were conducted to determine whether at least one combination produced a larger reduction in SeDBP at week 8 than the individual corresponding component doses, but did not compare BP reductions with different combination doses. Olmesartan medoxomil plus HCTZ produced greater reductions in both SeDBP and seated systolic blood pressure (SeSBP) at week 8 than did monotherapy with either component. All olmesartan medoxomil/HCTZ combinations significantly reduced SeDBP and SeSBP compared with placebo in a dose-dependent manner. Reductions from baseline in mean trough SeSBP/SeDBP were 3,3/8,2 mm Hg, 20,1/16,4 mm Hg, and 26,8/21,9 mm Hg with placebo, olmesartan medoxomil/HCTZ 20/12,5 mg, and olmesar-tan medoxomil/HCTZ 40/25 mg, respectively. All treatments were well tolerated. Olmesartan medoxomil/HCTZ combination therapy produced BP reductions of up to 26,8/21,9 mm Hg and was well tolerated.

1. BurtVL, Whelton P, Roccella EJ, Brown C, Cutler JA, HigginsM, Horan MJ, Labarthe D: Prevalence of hypertensionin theUS adult population: results from the Third National Health and Nutrition Examination Survey. 1988-1991. Hypertension 1995;25:305-313.

2. Hyman DJ, PavlikVN: Characteristics of patients withuncontrolled hypertension in the United States. N Engl J Med 2001;345:479486.

3. Chobanian AV. BakrisGL, Black HR. Cushman WC, Green LA, IzzoJLJr, JonesDW.Materson BJ, Oparil S, Wright IT Jr. Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection. Evaluation, andTreatment of HighBlood Pressure: the JNC7 Report. JAMA2003;289:2560-2572.

4. UKProspective DiabetesStudyGroup: Tightbloodpressure control ndrisk of macrovascular andmicrovascular complications in type 2 diabetes: UKPDS38. Br Med J 1998;317:703-713.

5. Hansson L, Zanchetti A, Carruthers SG, DahIOf B. Elmfe1dt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. for theHOT StudyGroup: Effectsof intensive blood-pressure loweringandlowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOl) randomised trial. Lancet 1998;351:1755-1762.

6. Kusek JW, Lee JY, Smith DE, Milligan S, Faulkner M, Comell CE, Kopple JD, Greene PG: Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996;17(SuppI4):40S-46S.

7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.

8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145153.

9. Cbrysant SG: Vascular remodeling: the role ofangiotensin-converting enzyme inhibitors. Am Heart J 1998;135: S21-830.

10. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685--691.

11. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect ofnisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insuIin-clependent diabetes and hypertension. N Engl J Med 1998;338:645--652.

12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.

13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators: Effects of Iosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nepbropathy. N Eng J Med 2001;345:861-869.

14. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz L for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.

15. Cohn IN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Eng! J Moo 2001;345:16671675.

16. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire D, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolcl. Lancet 2002;359:9951003.

17. American Diabetes Association: Diabetic nephropathy. Diabetes Care 2002;25(Suppl1): S85-S89.

18. Neutel JM: Clinical studies of CS-866, the newest angiotensin II receptor antagonist Am J Cardio12001;87(Suppl):37e-43C.

19. Stumpe KO, Ludwig M: Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002;16(SuppI2): S24-S28.

20. Van Mieghem W: A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension (Abstract). J Hypertens 2001;19(Suppl 2): S152S153.

21. Chrysant SG, Marbury T, Robinson TS: Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17:425432.

22. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J: Comparative efficacy ofolmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283291, 318.

23. Schrijver G, Weinberger: ME: Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979;25:33-42.

24. Pickkers P, Hughes AD, Russel FG, Thien T, Smits P: Thiazideinduced vasodilation in humans is mediated by potassium channel activation. Hypertension 1998;32:1071-1076.

25. Chrysant SG, for the Lisinopril-Hydrochlorothiazide Group: Antihypertensive effectiveness of low-dose lisinoprilhydrochlorothiazide combination: a large multicenter study. Arch InternMed 1994; 154:737-743.

26. Chrysant SG, Fagan T, Glazer R, Kriegman A: Effects ofbenazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med 1996;5:17-24.

27. Chrysant SG, Fox AA, Stimpel M: Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. Am J Hypertens 1995; 8:418-421.

28. Chrysant SG: Perindoprillhydrochlorothiazide dose combinations for the treatment of hypertension: a multicenter study. J Clin Pharmacol1997; 37:47-52.

29. Chrysant SG: Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med 1998;7:370-376.

30. Hung HM, Chi GY, Lipicky RJ: Testing for the existence of a desirable dose combination. Biometrics 1993;49:85-94.

31. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA: Matrix study of irbesartan with hydrochlorothiazide in mild-tomoderate hypertension. Am J Hypertens 1999;12:797-805.

32. Hansson L, Smith DH, Reeves R, Lapuerta P: Headache in mildto-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med 2000;160:1654-1658.

33. Estacio RO, Schrier RW: Antihypertensive therapy in type 2 diabetes: implications of the Appropriate Blood pressure Control in Diabetes (ABCD) trial. Am J CardioI1998;82(Supp1 9B):9R-14R.

34. Neutel JM, Smith DH, Weber MA: Low-dose combination therapy: an important first-line treatment in the management ofhypertension. Am J Hypertens 2001;14:286-292.

35. Chrysant SG, Womboldt DG, Feliciano N, Zheng H: Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Curr Ther Res 1998; 59:762-772.

36. Corvol P, Plouin PF: Angiotensin II receptor blockers: current status and future prospects. Drugs 2002;62:53--64.

37. Burnier M: Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-912.

38. Moser M, Black HR. The role of combination therapy in the treatment of hypertension. Am J Hypertens 1998;11:735-78S.